Wire · opportunities
AbbVie and Iambic: Partnering on AI-Powered Drug Discovery
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
AbbVie has partnered with Iambic, a biotech firm leveraging advanced AI technologies including a multimodal transformer model, to accelerate small-molecule drug discovery in immunology, neuroscience, and oncology. This collaboration aims to improve the precision and efficiency of drug candidate selection by optimising multiple molecular properties simultaneously.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 21 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
AbbVie's integration of Iambic's AI-driven molecular design offers founders in biotech a new standard for drug candidate optimisation, meaning you need to pitch your AI tools on precision gains or risk falling behind. Drug discovery is shifting from trial-and-error to scaled AI hypothesis testing, opening doors to partnerships for those with complementary capabilities.
◆ Coverage
3 sources · first reported 21 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics